Results of the first clinical trials suggested that CD19-directed CAR-T cells may bring benefits for CLL patients; however, the percentage of complete responses is significantly lower than in DLBCL or B-ALL patients [76,77]. Here, CD19 is linked to B-cell chronic lymphocytic leukemia.